Codexis (CDXS) | Stock Overview & Key Data
Codexis Performance Comparison
Stock Range
Today's Range
Low: $2.29
High: $2.43
on September 4, 2025
52 Week Range
Low: $1.90
High: $6.08
on April 7, 2025
on December 11, 2024
All-Time High: $42.01 on November 8, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$226.6M
EPS
-0.80
P/E Ratio (TTM)
-2.82
Forward P/E
-3.96
P/B Ratio
4.43
PEG Ratio
0.06
Div. Yield
N/A
ROE
-111.00%
Beta
2.551
Debt to Equity
124.00
Financial Highlights
Profitability
Gross Margin
86.31%
Operating Margin
-83.91%
Profit Margin
-113.67%
Returns and Earnings
Return on Assets (TTM)
-26.48%
Return on Equity (TTM)
-111.00%
EBITDA
$-52.3M
Net Income (TTM)
$-65.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.70
Quarterly Revenue Growth (YoY)
92.10%
Quarterly Earnings Growth (YoY)
92.10%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Codexis CDXS | 226.56M Micro-cap | -11.03% | -14.79% | 3.86% | -9.70% | -51.60% | -11.68% | -67.99% | -78.79% |
| Vertex VRTX | 102.81B Large-cap | 1.24% | -15.95% | -10.97% | -18.36% | -2.18% | -15.19% | 35.88% | 53.87% |
| Regeneron REGN | 61.25B Large-cap | -2.14% | -0.76% | 16.97% | -16.03% | -20.69% | -49.87% | -21.69% | 4.12% |
| Bright Minds DRUG | 245.98M Micro-cap | 3.10% | 23.91% | 59.53% | 36.36% | 6.91% | 3,562.50% | 459.87% | 64.30% |
| Atea Pharmaceuticals AVIR | 244.94M Micro-cap | -4.03% | -5.67% | 3.10% | 14.83% | -2.63% | -7.50% | -57.74% | -89.02% |
| Third Harmonic Bio THRD | 242.79M Micro-cap | 0.00% | -1.28% | 4.47% | 56.85% | -51.27% | -53.82% | -70.11% | -70.11% |
Ownership & Short Interest
Insider Ownership
2.29%
Institutional Ownership
80.71%
Shares Short
5M
Short Ratio
5.15
Short % of Shares Outstanding
5.84%
Average 10-Day Volume
1M
Average 90-Day Volume
1M
Warning: Undefined variable $nickname in /usr/local/lsws/wordpress/wp-content/themes/egnitech-devyara/templates/stock-overview.php on line 329
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is CDXS's 52-week high and low?
- In the last 52 weeks, Codexis reached a high of $6.08 (on December 11, 2024) and a low of $1.90 (on April 7, 2025).
- What is the market cap and P/E ratio for CDXS?
- Curious about Codexis's size and valuation? Its market capitalization stands at 226.56M. When it comes to valuation, the P/E ratio (trailing twelve months) is -2.82, and the forward P/E (looking ahead) is -3.96.
- Does CDXS pay dividends? If so, what's the yield?
- As for dividends, Codexis isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Codexis's main competitors or similar companies to consider before investing?
When looking at Codexis, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX102.81B Healthcare Biotechnology -15.19% 35.88% Regeneron
REGN61.25B Healthcare Biotechnology -49.87% -21.69% Bright Minds
DRUG245.98M Healthcare Biotechnology 3,562.50% 459.87% Atea Pharmaceuticals
AVIR244.94M Healthcare Biotechnology -7.50% -57.74% Third Harmonic Bio
THRD242.79M Healthcare Biotechnology -53.82% -70.11% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Codexis Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Codexis's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -111.00%, the Debt to Equity ratio from the most recent quarter is 124.00, and its Gross Profit Margin stands at 86.31%.
- What is the recent revenue and earnings growth for CDXS?
- Looking at Codexis's growth, its revenue over the trailing twelve months (TTM) was $57M. Compared to the same quarter last year (YoY), quarterly revenue grew by 92.10%, and quarterly earnings saw a YoY growth of 92.10%.
- How much of CDXS stock is held by insiders and institutions?
- Wondering who owns Codexis stock? Company insiders (like executives and directors) hold about 2.29% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 80.71%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.